Samsung BioLogics and F. Hoffmann-La Roche have entered into a long-term strategic manufacturing agreement under which Samsung will manufacture Roche’s commercial biologic medicines at its two manufacturing facilities in Incheon, South Korea. One of the facilities is currently under construction. Financial terms and products under the agreement were not disclosed.
 
“We are pleased to announce this strategic manufacturing relationship with Roche and look forward to delivering best-in-class manufacturing services with the highest global quality standards,” said Tae-Han Kim, president and chief executive officer of Samsung BioLogics. “This collaboration with the world’s largest biotech company is an important milestone for Samsung as it validates our long term strategy of becoming a leader in biopharmaceutical manufacturing.”